青蒿琥酯对人乳腺癌MCF-7血管生成和肿瘤浸润作用研究

中国临床药理学与治疗学 ›› 2015, Vol. 20 ›› Issue (5): 537-540.

青蒿琥酯对人乳腺癌MCF-7血管生成和肿瘤浸润作用研究

董海鹰¹, 王知非²

¹浙江省人民医院泌尿外科肿瘤中心, ²肝胆胰及微创外科,杭州 310034,浙江

收稿日期:2015-01-08 修回日期:2015-05-05 发布日期:2015-06-11
作者简介:董海鹰,女,博士,副主任医师,研究方向:肿瘤化疗临床及基础研究。Tel: 13958197763 E-mail: zhifei1973@126.com
基金资助:
黑龙江省青年科学技术专项资金项目(QC05C46);黑龙江省卫生厅资助( 2005-47);2014年浙江省中医药科学研究基金项目 (2014ZB004);2015年浙江省自然科学基金面上项目( LY15H160055);2015浙江省卫计委面上项目(201312171)

The effect of artesunate on angiogenesis and tumor infiltration in human breast carcinoma MCF-7

DONG Hai-ying¹, WANG Zhi-fei²

¹ Urology Tumor Center, Zhejiang Provincial People's Hospital Hepatobiliary, ² Pancreatic and Minimally Invasive Surgery Center, Hangzhou 310034, Zhejiang, China

Received:2015-01-08 Revised:2015-05-05 Published:2015-06-11

摘要/Abstract

摘要： 目的: 观察青蒿琥酯对人乳腺癌MCF-7血管生成及浸润转移的抑制作用。方法: 建立人乳腺癌MCF-7裸鼠移植瘤模型,给予不同剂量青蒿琥酯治疗并观察其对移植瘤的抑制作用;用免疫组化检测移植瘤组织细胞中VEGF、HIF-1α、uPA、E-cadherin蛋白表达和Western blot检测移植瘤组织细胞中HIF-1α、VEGF蛋白表达。结果: 青蒿琥酯低、高剂量组抑瘤率分别为(24.39±10.20) %、(40.24±7.02 ) %;免疫组化结果显示,与生理盐水组比较,青蒿琥酯低、高剂量组VEGF、HIF-1α蛋白表达显著降低,差异具有统计学意义(P<0.05); uPA和E-cadherin蛋白在生理盐水组和青蒿琥酯低、高剂量组中的表达水平差异均无统计学意义(P>0.05),HIF-1α/VEGF之间表达呈正相关(r=0.983,P=0.000);Western blot 结果显示,青蒿琥酯低、高剂量组中VEGF、HIF-1α蛋白下调,表达量低于生理盐水组,青蒿琥酯高剂量组的蛋白表达量最低。HIF-lα与VEGF蛋白表达之间存在一致性。结论: 青蒿琥酯可显著抑制乳腺癌裸鼠移植瘤的生长,其机制可能与抗肿瘤血管及抑制肿瘤侵袭相关。

关键词: 青蒿琥酯, 裸鼠, 乳腺癌, 血管生成, 浸润

Abstract: AIM: To explore the effect of artesunate on the angiogenesis and tumor infiltration in human breast carcinoma MCF-7.METHODS: The human breast tumor cell line MCF-7 was transplanted into nude mice, and the animals were treated with various doses of ART and normal saline (NS) was as control. The tumor inhibitory effects were measured and compared. The expression of angiogenesis-related proteins VEGF and HIF-1α were detected by immunohistochemistry and western blot.Urokinase plasminogen activator (uPA) and E-cadherin expressions were detected by immunohistochemistry .RESULTS: The tumor inhibition rates in the low dose ART group, high dose ART group were (24.39±10.20) % and (40.24±7.02 ) %, respectively. Immunohistochemical results showed that compared with the normal saline group, the expressions of VEGF and HIF-α were significantly reduced,there were statistically significant difference (P<0.05).And the expression levels of uPA and E-cadherin between the treatment groups and the normal saline group were statistically insignificant(P>0.05). The expression of HIF-lα and VEGF were positively correlated(r=0.983,P=0.000). Western blot results showed that compared with the normal saline group, the expressions of VEGF and HIF-1α were significantly reduced.CONCLUSION: Artesunate inhibits the growth of MCF-7 xenograft mouse,its mechanism is related to inhibiting angiogenesis and tumor infiltration .

Key words: artesunate, nude mice, breast cancer, angiogenesis, infiltration

中图分类号:

R965.2

董海鹰, 王知非. 青蒿琥酯对人乳腺癌MCF-7血管生成和肿瘤浸润作用研究[J]. 中国临床药理学与治疗学, 2015, 20(5): 537-540.

DONG Hai-ying, WANG Zhi-fei. The effect of artesunate on angiogenesis and tumor infiltration in human breast carcinoma MCF-7[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 537-540.

参考文献

[1] Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia inducible factor 1alpha during breast carcinogenesis[J]. J Natl Cancer Inst, 2001,93 (4):309-314.
[2] Choong PF,Nadesapillai AP.Urokinse plasminogen activator system:a multifunctional role in tumor progression and metastasis[J].Clin Orthop Relat Res,2003,415suppl:S46-S58.
[3] Li P, Yang S, Dou M,Synergic effects of artemisinin and resveratrol in cancer cells[J]. J Cancer Res Clin Oncol,2014,140(12):2065-2075.
[4] Chen HH, Zhou HJ, Wang WQ, et al. Antimalarial dihydroartemisinin also inhibits angiogenesis[J].Cancer Chemother Pharmacol, 2004, 53 (5):423-432.
[5] Murray J, Gannon S, Rawe S. In vitro oxygen availability modulates the effect of artesunate on HeLa cells[J]. Anticancer Res, 2014 ,34(12):7055-7060.
[7] Chen H, Shi L, Yang X. Artesunate inhibiting angiogenesis induced by human myeloma RPMI8226 cells[J]. Int J Hematol, 2010 ,92(4):587-597.
[7] Laughner E ,Taghavi P ,Chiles K, et al. HER2 signaling increases the rate of hypoxia-inducible HIF-1 synthesis :novel mechanism for HIF-1 mediated vascular endothelial growth foctor expression[J]. Mole Cell Biol,2001,21(12):3995-4004.
[8] Hui EP, Chan AT, Pezzella F, et al. Coexpression of hypoxia-inducible factors 1 alpha and 2 alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival[J].Clin Cancer Res,2002,8(8):2595-2604.
[9] Fisher JL, Mackie PS, Howard ML, et al. The expression of the urokinase plasmnogen activator system in metastatic murine osteosarcoma:an in vivo mouse mode[J]. Clin Cancer Res, 2001,7(6):1654-1660.
[10]来丽娜, 任泽恩, 杨柳絮, 等. ERK1/2信号通路在青蒿琥酯抑制PDGF-BB诱导HSC细胞增殖中的作用[J].中国临床药理学与治疗学, 2011,16(2):126-128.

[1]	廖梦玲, 汪艳, 罗静, 王诺妍, 华玲, 张瑜, 邓非, 袁月, 周军, 周红. 青蒿琥酯抑制巨噬细胞释放前炎症细胞因子的分子作用机制研究[J]. 中国临床药理学与治疗学, 2023, 28(9): 969-978.
[2]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[3]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[4]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[5]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[6]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[7]	陈柯羽, 黄圆, 王晓稼, 郑亚兵. 抗体偶联药物在乳腺癌中的临床应用与研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 898-909.
[8]	李梦茜, 张克兢, 夏凡. 乳腺癌疫苗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 918-925.
[9]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[10]	王智, 周鑫, 何雪茹, 付裕豪, 荀雪姣, 李颖, 董占军. 哌柏西利治疗乳腺癌的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 205-213.
[11]	王秀, 季麒麟, 裴文俊, 曾颖. 3-溴丙酮酸-胆固醇酯增强乳腺癌细胞对他莫昔芬敏感性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1093-1100.
[12]	武帅, 杨君, 郑云. 乳腺癌中具有双重功能的miRNA[J]. 中国临床药理学与治疗学, 2022, 27(7): 814-821.
[13]	施经斌, 熊阳. 肿瘤微环境与乳腺癌细胞互作导致肿瘤转移的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 562-574.
[14]	叶小弟, 缪云萍, 陈爱瑛, 程敏, 田雪君, 郑高利. 裸鼠原位非肌层浸润性膀胱癌模型的优选及验证[J]. 中国临床药理学与治疗学, 2022, 27(4): 473-480.
[15]	董伟, 黄小英, 谢冰斌, 汤喜兰, 李洪铭, 邱雨美, 赵国巍, 梁新丽. 氧化前胡素对乳腺癌MCF-7/DOX细胞多柔比星耐药的抑制作用[J]. 中国临床药理学与治疗学, 2022, 27(3): 260-266.